NEW YORK – Cancer drug developer Merus on Tuesday said it will collaborate with Erasmus University Medical Center in the Netherlands and National Cancer Center Japan to raise awareness of its eNRGy trial, which is evaluating the firm's HER2/3-targeting bispecific antibody zenocutuzumab in solid tumors characterized by rare NRG1 fusions.
To read the full story....
...and receive Weekly News bulletins.
Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.
Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.